Oxford BioMedica is a leading gene-based biopharmaceutical company developing innovative medicines to improve the lives of patients with high unmet medical needs. We have established platform technologies in gene delivery and immunotherapy, protected by an extensive intellectual property estate. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and is also widely used in the ex-vivo cell therapy arena.
Oxford BioMedica's product portfolio is focused on high value, growing markets. These include gene therapy products engineered to treat Parkinson's disease (preclinical, Phase I/II), Motor Neurone Disease (preclinical) and ocular diseases (preclinical), especially retinal diseases (Phase I and Phase I/II).
The Company also has a MHRA certified GMP manufacturing capability to produce Advanced Medicinal Products (AMP). In particular our focus is on viral manufacturing and development.